These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 31594218)

  • 1. Tau and Amyloid-β Pathology in Japanese Forensic Autopsy Series Under 40 Years of Age: Prevalence and Association with APOE Genotype and Suicide Risk.
    Yoshida K; Hata Y; Ichimata S; Nishida N
    J Alzheimers Dis; 2019; 72(2):641-652. PubMed ID: 31594218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early CA2 Tau Inclusions Do Not Distinguish an Age-Related Tauopathy from Early Alzheimer's Disease.
    Del Tredici K; Schön M; Feldengut S; Ghebremedhin E; Kaufman SK; Wiesner D; Roselli F; Mayer B; Amunts K; Braak H
    J Alzheimers Dis; 2024; 101(4):1333-1353. PubMed ID: 39302368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.
    Sunderland T; Mirza N; Putnam KT; Linker G; Bhupali D; Durham R; Soares H; Kimmel L; Friedman D; Bergeson J; Csako G; Levy JA; Bartko JJ; Cohen RM
    Biol Psychiatry; 2004 Nov; 56(9):670-6. PubMed ID: 15522251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tau pathology spread in PS19 tau transgenic mice following locus coeruleus (LC) injections of synthetic tau fibrils is determined by the LC's afferent and efferent connections.
    Iba M; McBride JD; Guo JL; Zhang B; Trojanowski JQ; Lee VM
    Acta Neuropathol; 2015 Sep; 130(3):349-62. PubMed ID: 26150341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Senile dementia associated with amyloid beta protein angiopathy and tau perivascular pathology but not neuritic plaques in patients homozygous for the APOE-epsilon4 allele.
    Vidal R; Calero M; Piccardo P; Farlow MR; Unverzagt FW; Méndez E; Jiménez-Huete A; Beavis R; Gallo G; Gomez-Tortosa E; Ghiso J; Hyman BT; Frangione B; Ghetti B
    Acta Neuropathol; 2000 Jul; 100(1):1-12. PubMed ID: 10912914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apolipoprotein E-epsilon4 alleles in cerebral amyloid angiopathy and cerebrovascular pathology associated with Alzheimer's disease.
    Premkumar DR; Cohen DL; Hedera P; Friedland RP; Kalaria RN
    Am J Pathol; 1996 Jun; 148(6):2083-95. PubMed ID: 8669492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The angiotensin 1-converting enzyme insertion (I)/deletion (D) polymorphism does not influence the extent of amyloid or tau pathology in patients with sporadic Alzheimer's disease.
    Lendon CL; Thaker U; Harris JM; McDonagh AM; Lambert JC; Chartier-Harlin MC; Iwatsubo T; Pickering-Brown SM; Mann DM
    Neurosci Lett; 2002 Aug; 328(3):314-8. PubMed ID: 12147333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
    Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
    JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. APOE epsilon 4 influences the pathological phenotype of Alzheimer's disease by favouring cerebrovascular over parenchymal accumulation of A beta protein.
    Chalmers K; Wilcock GK; Love S
    Neuropathol Appl Neurobiol; 2003 Jun; 29(3):231-8. PubMed ID: 12787320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic associations between cathepsin D exon 2 C-->T polymorphism and Alzheimer's disease, and pathological correlations with genotype.
    Davidson Y; Gibbons L; Pritchard A; Hardicre J; Wren J; Tian J; Shi J; Stopford C; Julien C; Thompson J; Payton A; Thaker U; Hayes AJ; Iwatsubo T; Pickering-Brown SM; Pendleton N; Horan MA; Burns A; Purandare N; Lendon CL; Neary D; Snowden JS; Mann DM
    J Neurol Neurosurg Psychiatry; 2006 Apr; 77(4):515-7. PubMed ID: 16543533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tau seeding activity begins in the transentorhinal/entorhinal regions and anticipates phospho-tau pathology in Alzheimer's disease and PART.
    Kaufman SK; Del Tredici K; Thomas TL; Braak H; Diamond MI
    Acta Neuropathol; 2018 Jul; 136(1):57-67. PubMed ID: 29752551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tau load is associated with apolipoprotein E genotype and the amount of amyloid beta protein, Abeta40, in sporadic and familial Alzheimer's disease.
    Thaker U; McDonagh AM; Iwatsubo T; Lendon CL; Pickering-Brown SM; Mann DM
    Neuropathol Appl Neurobiol; 2003 Feb; 29(1):35-44. PubMed ID: 12581338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predisposition to accelerated Alzheimer-related changes in the brains of human immunodeficiency virus negative opiate abusers.
    Anthony IC; Norrby KE; Dingwall T; Carnie FW; Millar T; Arango JC; Robertson R; Bell JE
    Brain; 2010 Dec; 133(Pt 12):3685-98. PubMed ID: 21126996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The spectrum of preclinical Alzheimer's disease pathology and its modulation by ApoE genotype.
    Pletnikova O; Kageyama Y; Rudow G; LaClair KD; Albert M; Crain BJ; Tian J; Fowler D; Troncoso JC
    Neurobiol Aging; 2018 Nov; 71():72-80. PubMed ID: 30099348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects.
    Toledo JB; Zetterberg H; van Harten AC; Glodzik L; Martinez-Lage P; Bocchio-Chiavetto L; Rami L; Hansson O; Sperling R; Engelborghs S; Osorio RS; Vanderstichele H; Vandijck M; Hampel H; Teipl S; Moghekar A; Albert M; Hu WT; Monge Argilés JA; Gorostidi A; Teunissen CE; De Deyn PP; Hyman BT; Molinuevo JL; Frisoni GB; Linazasoro G; de Leon MJ; van der Flier WM; Scheltens P; Blennow K; Shaw LM; Trojanowski JQ;
    Brain; 2015 Sep; 138(Pt 9):2701-15. PubMed ID: 26220940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Expression of apolipoprotein E in Alzheimer's disease and its significance].
    He SR; Liu DG; Wang S; Xia YJ
    Zhonghua Bing Li Xue Za Zhi; 2005 Sep; 34(9):556-60. PubMed ID: 16468304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiotensin-converting enzyme 2 is reduced in Alzheimer's disease in association with increasing amyloid-β and tau pathology.
    Kehoe PG; Wong S; Al Mulhim N; Palmer LE; Miners JS
    Alzheimers Res Ther; 2016 Nov; 8(1):50. PubMed ID: 27884212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apolipoprotein E-epsilon 2 and Alzheimer's disease: genotype influences pathologic phenotype.
    Lippa CF; Smith TW; Saunders AM; Hulette C; Pulaski-Salo D; Roses AD
    Neurology; 1997 Feb; 48(2):515-9. PubMed ID: 9040748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Argyrophilic grain pathology as a natural model of tau propagation.
    Rábano A; Rodal I; Cuadros R; Calero M; Hernández F; Ávila J
    J Alzheimers Dis; 2014; 40 Suppl 1():S123-33. PubMed ID: 24577470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between apolipoprotein E e4 allele and arteriosclerosis, cerebral amyloid angiopathy, and cerebral white matter damage in Alzheimer's disease.
    Tian J; Shi J; Bailey K; Lendon CL; Pickering-Brown SM; Mann DM
    J Neurol Neurosurg Psychiatry; 2004 May; 75(5):696-9. PubMed ID: 15090562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.